Article ID Journal Published Year Pages File Type
5605484 International Journal of Cardiology 2017 9 Pages PDF
Abstract
Ambrisentan could be considered as the most appropriate therapy among the four ERAs for PAH patients. Bosentan also behaved well, but it is not as safe as ambrisentan.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis
Authors
, ,